PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
Dutasteride and finasteride can affect libido differently, with some experiencing increased libido and others decreased libido or erectile dysfunction. Dutasteride may increase testosterone levels but can also cause side effects like liver enzyme changes, while topical finasteride may have fewer sexual side effects.
Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.
Diluting finasteride in a Hims spray can be done using ethanol or propylene glycol to maintain the desired concentration without increasing minoxidil levels. This approach ensures the finasteride concentration is reduced to 0.025% without affecting the minoxidil strength.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
The user started using finasteride, minoxidil, and biotin for hair loss and believes they are a hyper responder, noticing significant changes in hair thickness. They regret not starting earlier and mention using oral minoxidil.
PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.
The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
Hair loss treatments Finasteride and Dutasteride are discussed, with emphasis on their safety and effectiveness. Users share frustration about fear-mongering and side effect discussions, suggesting trust in scientific studies and FDA approval.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.
The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.
Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.
The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.
User started using Pantostin Alfatradiol after watching haircafe on YouTube and noticed thicker hair. They wonder why it's not more popular, as it's a 5α-reductase inhibitor with a different mechanism than minoxidil.